Stage IIIB Breast Cancer Recruiting Phase 1 / 2 Trials for Cobimetinib (DB05239)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03566485Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerTreatment